Orthocell Ltd's (ASX:OCC) Paul Anderson caught up with Proactive soon after receiving positive results from a US 510(k) animal pilot study, indicating that CelGro® facilitates superior nerve regeneration when compared to the market-leading nerve repair device - restoring the sciatic nerve to a pre-injured state. As a result of this breakthrough nerve regeneration data, and in light of the previously released interim human clinical data, the company is evaluating the medical device US regulatory pathways to identify opportunities for expedited approval of CelGro® and the ideal route to the highest reimbursement value.
Orthocell identifying opportunities for expedited approval of CelGro after 'breakthrough' results
Quick facts: Orthocell Ltd
Price: 0.51 AUD
Market Cap: $97.68 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...FOR OUR FULL DISCLAIMER CLICK HERE